tbuckley/cabot-search huggingface dataset:
AB0311 Results of screening for tuberculosis infection in patients with rheumatoid arthritis before and on treatment with biological dmards
Authors: D Karateev, S Borisov, T Fomina, G Loukina, E Luchikhina, L Guntupova, A Satybaldyev
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> The prevalence of tuberculosis infection in Russia is much higher than in Western Europe. Therefore, screening for TB infection in patients with RA before therapy with biological agents is of particular importance. At the same time, reliable information on the results of screening are very few. <h3>Objectives</h3> Explore the results of the application of different methods of diagnosis of tuberculosis infection in RA patients before and during treatment with biological agents. <h3>Methods</h3> We used the data from the Russian register "Observational REgister of arthritis in cLinical practice" (OREL). 1471 RA patients were screened for TB infection before prescribing biologics, of whom 829 patients were exposed to TB infection monitoring on therapy by biologics. The group included 21.1% men, 78.9% women; at the time of initial screening age was 50,0±0,4 years, the duration of the disease 8,5±3,8 yrs, 68,3% RF +, 85.1% anti-CCP +, DAS28-ESR 5,7±1,1, 95,7% used synthetic DMARDs, 60,1% used systemic steroids. We used PPD (Mantoux) test, Diaskin test (intradermal test with tuberculosis recombinant allergens CFP10-ESAT6) and QuantiFERON-TB Gold (QFT) test (in some patients), chest X-ray, chest CT scan (if needed), all the patients were consulted by phthisiatrician. PPD and Diaskin test results were considered positive if the papule was ≥5 mm. Duration of treatment with biologics (anti-TNFs and others) varied widely (2–154 months), making a total of 2552,4 patient-years. <h3>Results</h3> At screening, we got 40,3% positive results of PPD test (significantly more in younger patients and patients who did not receive steroids), 16,5% positive results of Diaskin test (with no significant correlations with age and steroids). Positive results matched in 19.9% of cases, negative - in 51.9%. Discordant results in 217 patients were in 92,2% cases related to negative results of Diaskin in PPD-positive persons. Active TB was found after additional examination in 3 (0,2%) patients, inactive TB-related changes were revealed in 124 (8,8%) patients. Positive PPD and Diaskin results, but not QFT, correlated with signs of inactive TB lesions. Positive results of PPD and QFT tests matched in 36.5% of cases, negative - in 18.7%, Diaskin and QFT – in 33,6% and 41,1% of cases resp. As a result of screening, 224 pts were treated by isoniazid or combination of anti-TB drugs before initiation of biologics. On treatment with biologics, 114 (13,7%) pts became PPD-positive and 56 (6,8%) Diaskin positive, active TB was diagnosed in 8 (0,97%) pts. <h3>Conclusions</h3> In carrying out TB screening before prescribing biologics in high-risk population of TB infection it is reasonable to use both PPD and Diaskin tests, and repeat them every 6 months on treatment. <h3>Disclosure of Interest</h3> None declared
AB0901 Clinical significance of urate deposition in tendon: a dual-energy ct study
Authors: Y Eun, IY Kim, H Jeong, E-J Park, H Kim, J Lee, E-M Koh, H-S Cha
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Dual-energy computed tomography (DECT) is advanced imaging modality that shows the deposition of monosodium urate (MSU) crystal in tissue as a color signal. The MSU crystal deposit around the symptomatic joint is considered as positive finding, but the clinical significance of urate deposition around the tendon is still unclear. <h3>Objectives</h3> The aim of this study was to compare the clinical characteristics and DECT findings in people with MSU crystal deposition in the joints and people with urate deposition in the tendons. <h3>Methods</h3> DECT was performed in 71 patients who complained of recurrent painful swelling of the joints, and 35 of them showed MSU crystal deposition in the joints on DECT. Clinical manifestation and serum uric acid level data were collected. <h3>Results</h3> Most of the included patients were middle-aged (mean age 50 years, SD 15) and 67 patients (94%) were male. All patients who had MSU crystal deposition in joints on DECT had a history of typical gout attacks, and 29 patients (81%) had a history of gout attacks among patients with urate deposition only in tendons (<i>p</i>=0.011). The mean uric acid level of patients included in the study was as high as 7.5±2.2 mg/dL. In the highest uric acid level, the absolute value was higher in patients with urate deposition in joints, but there was no statistical significance. The correlation between the gout attack site and the urate deposit sites was 91% in patients with joint involvement, but only 6% in patients without joint involvement (<i>p</i>&lt;0.001). There were 4 patients (11%) who showed gouty erosion without MSU crystal deposition in joints on DECT. <h3>Conclusions</h3> The MSU crystal deposition in the tendon was not correlated well with clinical features, suggesting that it is more likely to be associated with artifact or asymptomatic hyperuricemia. However, in some patients, MSU crystal deposition may be observed only in the tendon, even with gouty erosion. Therefore, careful interpretation of the DECT results is necessary. <h3>Disclosure of Interest</h3> None declared
FRI0739-HPR A rheumatology patientpanel: the patient is the expert, we are the specialist
Authors: JE Voorneveld-Nieuwenhuis, MD Kok, N Basoski, M Holtrop, D Lopes Barreto
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Patient participation is known in the field of rheumatology research and is becoming more customary. The patient perspective can improve the care and line specific needs of the patient to the delivered care.Recently, ourRheumatology department within the Maasstad Hospital introduced the Value Based Health Care principle in order to optimize the current healthcare system. We thought to measure the value for patients we should let them participate in the project and asked them about what is of value for them and what are there goals. A good reason to start with a patient panel. <h3>Objectives</h3> For this reason we aimed to create a patient panel of rheumatology patients that are well informed and prepared to actively cooperate and participate in research, and co-design novel healthcare strategies. <h3>Methods</h3> Staff members (e.g. doctors and nurses) were asked to nominate patients that are expected to actively participate in the panel. Nominated patients were verbally approached and asked to participate. After mutual agreement a contract was signed were patients discretion was warranted, the capacity to handle confidential information was assessed and equality between members of the panel and staff was ensured. Enlargement of the panel is primarily staff-driven, but panel members are also invited to actively recruit other rheumatology patients. <h3>Results</h3> The initial enrolment period lasted for six months. Thereafter, meetings were organized were discussion were held on various themes such as goals and value for rheumatology patients. Additionally, a focus group of rheumatoid arthritis (RA) patients was assembled to evaluate a PROMs measurement tool. To date, a number of four panel discussion have been held. Currently, our patient panel consists of 54 patients with all kinds of rheumatic diseases. Their demographic and clinical data are presented in Table 1. Our panel has been asked to participate in other (hospital-wide) programmes including the development and evaluation of a patient portal. We organize about three meetings for the whole panel every year and arrange focus group meetings to discuss specific subjects. <h3>Conclusions</h3> Panel members are very open and enthusiastic. Some quotes: "I9m happy to do something in return for the good care I receive.", and "I want to promote participation in scientific research". Deployment of patient participation for co-creating innovations alongside research is an asset these days to connect changes to patients perception. In real live involving patient as an expert is not an effortless action for both patients and the expert care takers, it leads to satisfaction and an effective treatment. <h3>Disclosure of Interest</h3> None declared
SAT0265 Clinical characteristics of systemic lupus erythrematosus in an egyptian population: a retrospective cohort
Authors: B Medhat, T El Hadidi, K El Hadidi, A Yousri, D Hassan, F Talaat, L Maged, M Shabaan, M Eissa, N Hamdy El Gobashy, N Sobhy, N Abd El Baki, R El Refai, S Ghoneim, W AbdRahman
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Systemic lupus erythrematosus (SLE) is an autoimmune disease with a myriad of manifestations, that could vary among different ethnic and racial groups. <h3>Objectives</h3> To study the prevalence of various manifestations of SLE in an Egyptian population. <h3>Methods</h3> Information in this study was derived from the medical records of SLE patients who followed up in a private clinic in Cairo from January 1980 to June 2016. <h3>Results</h3> This descriptive retrospective case series included 1109 juvenile (19.4%) and adult (80.6%) patients, of which 114 (10.3%) were males and 995 were females (89.7%). Age of onset showed a mean of 26±11.19 years, and the mean of disease duration was 48.78±58.46 months (median: 26 years). The most common manifestations were synovitis (76.7%), malar rash (48.5%), leukopenia (45.7%), and photosensitivity (45.6%). At least one of the antiphospholipid antibodies was present in 41.8% of the patients tested for APL (636 patients). However thromboembolic manifestations and/or recurrent fetal loss occured in 11.5% of the patients. Neuropsychiatric manifestations were evident only in 6.4% of the patients, with seizures being the most common neuropsychiatric manifestation, present in 4% of the patients. 33.1% of the patients had nephritis, which followed the onset of the disease by a mean duration of 20±21.3 months (median=12 months). There were gender differences in the disease characteristics. Cutaneous vasculitis, nephritis, and hypocomplementemia were statistically higher in males (p=0.012, p=0.01, and p=0.041 respectively). Whereas, synovitis, and alopecia were statistically higher in females (p=0.012 and p=0.006 respectively). Patients with juvenile onset had a statisticaly higher frequency of nephritis (0=0.01), seizures (p=0.012) haemolytic anemia (p=0.001), and hypocomplementinemia (p=0.02). <h3>Conclusions</h3> Synovitis and malar rash were the most common manifestations in our study. Secondary antiphospholipid was present in 11.5% of the patients. Male patients and juvenile patients showed a tendency towards a more severe disease. <h3>Disclosure of Interest</h3> None declared
Trastuzumab duration effects within patient prognostic subgroups in the PHARE trial.
Authors: Xavier B. Pivot, Thomas Denis Bachelot, Marc Debled, Jean-Yves Pierga, Pierre Kerbrat, Marc Espie, Pierre Fumoleau, David Khayat, Iris Pauporte, Gilles Romieu, Andrew Kramar
Journal: Journal of Clinical Oncology (2014)

600 Background: At 42.5 months of median follow-up, PHARE failed to show that 6 was non-inferior to 12 month of adjuvant trastuzumab. From the results of PHARE questions remain regarding whether the magnitude of benefit derived from 1 year is sufficient to justify its systematic use for different patient subgroups. Methods: Treatment effects were evaluated according to various tumour characteristics, and multivariate Cox proportional hazards regression models were performed on metastatic disease free survival (M-DFS) in the 12 month control arm. A prognostic score was defined providing the identification of patient categories with similar risks. The 6 months arm was used as a validation set in order to test for heterogeneity. Results: A total of 261 M-DFS events were observed and 4 prognostic groups were defined: very low, low, intermediate and high risks. In the 12 month arm, the corresponding 3-year M-DFS rates were 98.3%, 95.8%, 90.4% and 78.4% in the 4 prognostic groups, respectively. In the 6 month arm, the 3-year M-DFS rates were 98.3%, 94.2%, 85.7%, and 74.8% in the 4 prognostic groups, respectively. Conclusions: In the very low risk and low risk groups, the potential absolute benefit of standard duration of trastuzumab was small enough to indicate that optimal standard treatment might be clinically questionable. On the other hand, the 3-year metastasis occurrence rates strongly support the need for a search of a more efficient treatment in the intermediate and high risk groups. Clinical trial information: NCT00381901.
Long-term quality of life after peroral endoscopic myotomy remains compromised in patients with achalasia type III
Authors: Oscar Hernández Mondragón, Marina González Martinez, Juan Blancas Valencia, Maria Hernandez Reyes, Omar Solórzano Pineda, Gerardo Blanco Velasco
Journal: Endoscopy (2017)

Background and study aims Peroral endoscopic myotomy (POEM) is an excellent endoscopic treatment for achalasia. Clinical and manometric parameters are used for evaluation and follow-up. However, clinical success does not guarantee high quality of life (QoL) scores, generating doubts about their direct relationship. We aimed to evaluate QoL scores before and after POEM at medium and long term, to evaluate differences between achalasia subtypes and find which factors related to low QoL scores. Patients and methods Achalasia-confirmed patients undergoing POEM between February 2012 and November 2016. and completing at least 1 year of follow-up, were included. Assessment before and at 1, 6, 12, 24, 36 and 48 months after POEM employed manometry, barium series, Eckardt score, and the AE-18 health-related QoL scale. Demographic, clinical, and procedure characteristics were documented, with comparisons between subgroups. Multiple logistic regression analysis was done. Results 65 of 88 patients were included (38 women, 27 men; median age 47 years, interquartile range [IQR] 20 - 81), and 50 (76.9 %) completed 4 years of follow-up. Eckardt score improved (median, preprocedure 10 vs. post-procedure 2; P = 0.002) and this persisted. There was initial improvement in median integrated relaxation pressure (IRP) (29.4 mmHg [16 - 55] vs. 10.3 mmHg [3 - 18]; P = 0.000) and median QoL scores (40 vs. 68 at 1 month; P = 0.002); however IRP increased and QoL scores decreased. Men with confirmed type III achalasia had low QoL scores. Conclusions All patients had significant clinical improvement after POEM, with medium- to long-term persistence. Though quality of life and IRP initially improved, they deteriorated in the long term. Male sex and type III achalasia seem to be associated with low QoL scores.
Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
Authors: Rury R. Holman, M. Angelyn Bethel, Robert J. Mentz, Vivian P. Thompson, Yuliya Lokhnygina, John B. Buse, Juliana C. Chan, Jasmine Choi, Stephanie M. Gustavson, Nayyar Iqbal, Aldo P. Maggioni, Steven P. Marso, Peter Öhman, Neha J. Pagidipati, Neil Poulter, Ambady Ramachandran, Bernard Zinman, Adrian F. Hernandez
Journal: New England Journal of Medicine (2017)

The cardiovascular effects of adding once-weekly treatment with exenatide to usual care in patients with type 2 diabetes are unknown.We randomly assigned patients with type 2 diabetes, with or without previous cardiovascular disease, to receive subcutaneous injections of extended-release exenatide at a dose of 2 mg or matching placebo once weekly. The primary composite outcome was the first occurrence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. The coprimary hypotheses were that exenatide, administered once weekly, would be noninferior to placebo with respect to safety and superior to placebo with respect to efficacy.In all, 14,752 patients (of whom 10,782 [73.1%] had previous cardiovascular disease) were followed for a median of 3.2 years (interquartile range, 2.2 to 4.4). A primary composite outcome event occurred in 839 of 7356 patients (11.4%; 3.7 events per 100 person-years) in the exenatide group and in 905 of 7396 patients (12.2%; 4.0 events per 100 person-years) in the placebo group (hazard ratio, 0.91; 95% confidence interval [CI], 0.83 to 1.00), with the intention-to-treat analysis indicating that exenatide, administered once weekly, was noninferior to placebo with respect to safety (P<0.001 for noninferiority) but was not superior to placebo with respect to efficacy (P=0.06 for superiority). The rates of death from cardiovascular causes, fatal or nonfatal myocardial infarction, fatal or nonfatal stroke, hospitalization for heart failure, and hospitalization for acute coronary syndrome, and the incidence of acute pancreatitis, pancreatic cancer, medullary thyroid carcinoma, and serious adverse events did not differ significantly between the two groups.Among patients with type 2 diabetes with or without previous cardiovascular disease, the incidence of major adverse cardiovascular events did not differ significantly between patients who received exenatide and those who received placebo. (Funded by Amylin Pharmaceuticals; EXSCEL ClinicalTrials.gov number, NCT01144338 .).
BB Guns That Look Like Real Guns
Authors: Katherine E. M. Hoops, Stephen P. Teret
Journal: JAMA Pediatrics (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Concomitant Chemotherapy and Radiotherapy with SBRT Boost for Unresectable Stage III Non–Small Cell Lung Cancer: A Phase I Study
Authors: Kristin A. Higgins, Rathi N. Pillai, Zhengjia Chen, Sibo Tian, Chao Zhang, Pretesh Patel, Suchita Pakkala, Jay Shelton, Seth D. Force, Felix G. Fernandez, Conor E. Steuer, Taofeek K. Owonikoko, Suresh S. Ramalingam, Jeffrey D. Bradley, Walter J. Curran
Journal: Journal of Thoracic Oncology (2017)
A Circular RNA Binds To and Activates AKT Phosphorylation and Nuclear Localization Reducing Apoptosis and Enhancing Cardiac Repair
Authors: Yan Zeng, William W Du, Yingya Wu, Zhenguo Yang, Faryal Mehwish Awan, Xiangmin Li, Weining Yang, Chao Zhang, Qi Yang, Albert Yee, Yu Chen, Fenghua Yang, Huan Sun, Ren Huang, Albert J Yee, Ren-Ke Li, Zhongkai Wu, Peter H Backx, Burton B Yang
Journal: Theranostics (2017)

As central nodes in cardiomyocyte signaling, nuclear AKT appears to play a cardio-protective role in cardiovascular disease. Here we describe a circular RNA, circ-Amotl1 that is highly expressed in neonatal human cardiac tissue, and potentiates AKT-enhanced cardiomyocyte survival. We hypothesize that circ-Amotl1 binds to PDK1 and AKT1, leading to AKT1 phosphorylation and nuclear translocation. In primary cardiomyocytes, epithelial cells, and endothelial cells, we found that forced circ-Amotl1 expression increased the nuclear fraction of pAKT. We further detected increased nuclear pAKT in circ-Amotl1-treated hearts. In vivo, circ-Amotl1 expression was also found to be protective against Doxorubicin (Dox)-induced cardiomyopathy. Putative PDK1- and AKT1-binding sites were then identified in silico. Blocking oligonucleotides could reverse the effects of exogenous circ-Amotl1. We conclude that circ-Amotl1 physically binds to both PDK1 and AKT1, facilitating the cardio-protective nuclear translocation of pAKT.
FRI0247 Median time to low disease activity is shorter in tocilizumab combination therapy with csdmards as compared to monotherapy in patients with active rheumatoid arthritis and inadequate responses to csdmards and/or tnf inhibitors: subanalysis of the swiss and austrian patients from the act-sure study
Authors: R Mueller, W Graninger, P Sidiropoulos, C Goger, J von Kempis
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> To analyze efficacy and safety of tocilizumab in patients with rheumatoid arthritis (RA) and an inadequate response to conventional synthetic disease modifying anti-rheumatic drugs (csDMARDs) and/or tumour necrosis factor (TNF) inhibitors of the Swiss and Austrian patients from the ACT-SURE study. <h3>Objectives</h3> <h3>Methods</h3> Sub-analysis of RA patients from Switzerland and Austria, who participated in the international phase IIIb, open-label, ACT-SURE study. Patients with an inadequate response to csDMARDs or TNF antagonists were included into the study receiving 8 mg/kg of IV tocilizumab every 4 weeks during a 24 week time period. Therapy with one or more csDMARDs could be continued as combination therapy with tocilizumab (Combo) or stopped, resulting in tocilizumab monotherapy (Mono), at the treating physician9s discretion. These two patient groups were analyzed in separate and compared. <h3>Results</h3> Overall, 107 (22 on Mono vs 85 on Combo and) patients were treated with tocilizumab. The percentage of patients with at least one adverse event was significantly lower in the tocilizumab combination (58.8%) as compared to the monotherapy group (81.8%, p=0.0458). No differences in ACR20/50/70/90 response rates were observed between both treatment groups at week 24 (Mono: 63.6%, 40.9%, 22.7%, and 18.2% vs. Combo: 61.2%, 43.5%, 25.9%, and 10.6%). The median time to low disease activity (LDA) was significantly shorter in patients treated with tocilizumab combination therapy Mono: 9.1, Combo 7.9 weeks, Log Rank p=0.038). <h3>Conclusions</h3> In this post hoc regional sub-analysis of the ACT-SURE study no differences for disease activity were found comparing the two patient groups at week 24. However, median time to LDA was statistically shorter in patients treated with tocilizumab combination therapy as compared to tocilizumab monotherapy. Consequently, adding tocilizumab to csDMARD therapy rather than changing to tocilizumab monotherapy may be, in our opinion, the safest strategy to reach maximum effect in RA patients with active disease despite treatment with csDMARD. csDMARDs can be withdrawn either immediately due to adverse events or after at least low disease activity has been reached. <h3>Disclosure of Interest</h3> None declared